Peter Kassel Presents HealthySole at LSI USA '23

Transcription

Peter Kassel  0:05  

Hello, my name is Peter Kassel and I am CEO and co founder of HealthySole. We're the first third party validated product that uses UVC light to disinfect the soles of shoes. The reason why something like this is so important is because infections are going to be an increasingly important issue within healthcare and the society as a whole. There are a number of issues that are coming down the pike at the same time, which really create a combined pain point for what we're dealing with. And the issue is when these things are a problem, it all rolls downhill hospitals and patients are the ones paying the price. Whether you're dealing with numbers of infections, like the following, or the fact that hospitals are on the hook for the the price of all of this care, you're looking at potentially 35 to 50 billion loss by hospitals in the US annually and 92,000 deaths. We are looking at one of the most under addressed and under appreciated pathogen vectors, which is the soles of shoes. If you think of everywhere you've been today, all of the places that hospital physician goes, every patient that they visit, this is taken from with them from room to room. If you make the connection then of the dust in the top of your bookshelf at home. This is the same thing that happens in a hospital with air crystallization that happens with every step depositing, which happens at touch surfaces and instruments at all kinds of levels. What we're dealing with in hospitals is that we really have one method of doing it, which is at the beginning of every shift, somebody comes in, they mop the floor, they leave they you know wipe other surfaces as well. CDC research shows that within three hours, you're at full microbial load. So that means that if you're doing a 12 hour cleaning, you've got nine hours of infection, or 21 hours if you're dealing with a 24 hour a day cycle. With this product, you stand on it for eight seconds, it exposes the soul of your shoe, we see a two to three log kill reduction of viruses and bacteria slightly lower for spores based upon how fungus works with the with UVC. And it fits into all kinds of existing protocols, there's no need to replace materials, you don't have to retrofit anything, it just plugs right into the wall. These are our killed rates within a eight second cycle. These were third party done not ourselves. And these are the greatest issues that our hospitals are dealing with in terms of infection rates in our current era. To test our efficacy, we worked with the University of Houston School of Pharmacy, and we took a DNA tag strain of E. coli spike the soul of a shoe then moved through a mock hospital room for 15 minutes, no contact was made with the room otherwise, then hundreds of swabs were taken of each of these surfaces. The red number is the number of positive swabs for that Ecoli 96% of the swabs showed the E coli that was on the sole of the shoe on the surface of the patient within 15 minutes. When using our product, we saw reductions of nearly 90% on the bed and the furniture 86% on the patient 83% on the floor. So that means that we are essentially dealing with one of the largest contributors of pathogen load from entering into a patient's room. For this reason, we've been adopted by some of the most prestigious and diligent groups in the country or the world. App V. National Institute of Health internally tested the unit for six months prior to then adopting it and Frederick's Labs, which does safety and efficacy testing. For the FDA involving case AIDS, cancer and vaccine medications. Veterans Affairs has placed it within their long term extended living environments, and more. What we see is a massive market size for a technology like this due to its ability to be applied ubiquitously. We see a 150 song, a million song within the US with a tam of 2.8. There's already been large adopt. Well, there's been adoption of the product within European and Asian countries. And we expect there to be about a 7 billion additional tam when looking at the worldwide market. We've already been focusing on hospitals and long term extended care. But we've been approached by groups like Los Angeles Police Department to retrofit these units into many of their precincts. So we see an enormous amount of opportunity. We've been in the large confectioners factory, there are corrections facilities, commercial facilities, all of these have approached us and adopted it. Our growth strategy is to do what many would nail down a lot of the biggest areas within the United States that have large health facilities. We plan to actually leverage many thought leaders in such within the epidemiology world and the CDC circle and all of that, as well as continuing to expand our marketing and research. We outperform competitors, because there really isn't one that deals with this problem. booties were invented to deal with biological soiling of shoes it was to prevent anything that fell off of a PE Shouldn't from soiling the doctors shoes yet we've adopted them as a process for attempting to mitigate microbiology spread. Wet baths in the hospital situation are clearly a non starter. And there's one metoo product that's entered the market that is roughly six times the price of our unit and has regulatory issues due to the fact that they offload ozone within the process of generating their UVC gas. Our product currently sells for 5600. We're working right now to move to a medical manufacturer in Taiwan, we're going to cut the cost of version one in half in terms of manufacturing, and instantly begin developing version two, which will cut the costs in half again, our target is to be considered in the same price range as a Dyson Airblade hairdryer, hand dryer and the restroom. Those sell for $1,600 and are easily sold to all kinds of areas, we see this as an opportunity for our product to do the same. as well. We've opted for a very simple manufacturing process, which also involves our patent. And this allows us to scale quickly and to adopt the product into a number of verticals. We have some great patents. We are have three utility patents in the United States. These are actually really, really well protect our product, and have been issued to us in Japan, China, South Korea, Spain, and we're awaiting approval in India. We chose these areas strategically, they're massive manufacturers for each of their territory. So we saw the opportunity to kneecap anybody who was going to try and take over any of those territories. Our management team has a wide range of experience. We have experience in selling new technologies via modern methods. We have some of the most important phases in infection control who have been a part of trying to deal with this process. Since the initial Mercer outbreak of the early aughts. Our chairman has two successful IPO exits, which allow us the opportunity to understand the process and best exit to our ability. And we have a pathway to exit that we believe is one for success. We're moving the manufacturing off shores, we're going to use continued marketing and scaling campaigns. We also want to establish a market or an office in the European Union. The idea is to use pilot studies in the smaller countries so as to drive adoption across Europe or collect numbers that can be submitted in the United States for random controlled trials. We also see a five year revenue of about 90 million in the US. This is due to the fact that it's a we've been approached by so many different verticals to adopt the product. And we see a potential for about 30 million within Europe in that period of time as well. Our goal is to raise 15 million with a Regulation D, we have a Regulation A currently open that we believe will generate an extra five to 10 million. But with this amount we believe we're well positioned to drive the marketing necessary and have the success we need for an exit. So I appreciate your time. I would welcome any conversations or questions and I'm Peter Castle, CEO of HealthySole. Thank you.